Please login to the form below

Not currently logged in
Email:
Password:

idelalisib

This page shows the latest idelalisib news and features for those working in and with pharma, biotech and healthcare.

AbbVie's venetoclax set for early access in UK

AbbVie's venetoclax set for early access in UK

cell receptor pathway inhibitor therapy such as Johnson &Johnson's BTK inhibitor Imbruvica (ibrutinib) or Gilead Sciences' Zydelig (idelalisib).

Latest news

More from news
Approximately 4 fully matching, plus 23 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Hamell

Hamell is a full service behaviour change agency with a focus on delivering sustained change through a deep understanding of...

Latest intelligence

A stumble, but not a fall – what’s next for Opdivo?
Blue Latitude Health's Louis Perdios talks about the daunting challenges faced by BMS after Opdivo's disappointing results....
Blog: A new 'At your service' model for pharma
Turning the traditional sales model on its head to deliver commercial outcomes without selling at all...
london-conferences-anthill.jpg
Meet Anthill at conferences in London
October, the month of multichannel pharma marketing in London. Meet us at DigiPharm and Multichannel Excellence Summit...

Infographics